ログインで組織・契約価格をご覧ください。
サイズを選択してください
この商品について
化学式:
HSCH2CH(NHCOCH3)CO2H
CAS番号:
分子量:
163.19
EC Number:
210-498-3
UNSPSC Code:
12352209
NACRES:
NA.24
Beilstein/REAXYS Number:
1724426
MDL number:
製品名
N-アセチル-L-システイン, British Pharmacopoeia (BP) Reference Standard
InChI key
PWKSKIMOESPYIA-BYPYZUCNSA-N
InChI
1S/C5H9NO3S/c1-3(7)6-4(2-10)5(8)9/h4,10H,2H2,1H3,(H,6,7)(H,8,9)/t4-/m0/s1
SMILES string
CC(=O)N[C@@H](CS)C(O)=O
grade
pharmaceutical primary standard
API family
acetylcysteine
form
crystalline
shelf life
limited shelf life, expiry date on the label
manufacturer/tradename
BP
mp
106-108 °C (lit.)
application(s)
pharmaceutical
pharmaceutical small molecule
format
neat
storage temp.
2-8°C
類似した製品をお探しですか？ 訪問 製品比較ガイド
Biochem/physiol Actions
抗酸化物質であり、粘液溶解薬でもあります。細胞内のフリーラジカルスカベンジャー蓄積量を増加させます。神経細胞のアポトーシスを防止する性質が報告されていますが、平滑筋細胞ではアポトーシスを誘導します。HIVの複製を阻害します。ミクロソームのグルタチオントランスフェラーゼの基質です。
Application
Acetylcysteine BP Reference standard, intended for use in laboratory tests only as specifically prescribed in the British Pharmacopoeia.
Also used in monographs such as:Acetylcysteine Eye Drops
Also used in monographs such as:
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Other Notes
Sales restrictions may apply.
Packaging
Unit quantity: 200 mg. Subject to change. The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity please visit British Pharmacopoeia
signalword
Warning
hcodes
Hazard Classifications
Eye Irrit. 2
保管分類
13 - Non Combustible Solids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
Hongge Wang et al.
Oncogene, 39(14), 2905-2920 (2020-02-08)
PARP1 and PARP2 play critical roles in regulating DNA repair and PARP inhibitors have been approved for the treatment of BRCA1/2-mutated ovarian and breast cancers. It has long been known that PARP inhibition sensitizes cancer cells to DNA-damaging cytotoxic agents
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）